01
Cash & equivalents increased 584.1%
Cash & equivalents changed +584.1% from the comparable as-filed period.
$32.8M→$224.5MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTROCKET PHARMACEUTICALS, INC.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +584.1% from the comparable as-filed period.
Net income changed +278.8% from the comparable as-filed period.
Operating income changed +34.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
RCKT · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001140361-26-033915SEC ↗4Aug 20, 2026Period Aug 18, 20260001140361-26-033913SEC ↗4Aug 17, 2026Period Aug 13, 20260001140361-26-033417SEC ↗4Aug 17, 2026Period Aug 13, 20260001140361-26-033413SEC ↗4Aug 13, 2026Period Aug 11, 20260001140361-26-032818SEC ↗4Aug 13, 2026Period Aug 11, 20260001140361-26-032816SEC ↗8-KAug 10, 2026Period Aug 10, 20260001140361-26-032028SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 18, 2026Filed Aug 20, 2026 | Wilson MartinGeneral Counsel | Open Market SaleDirect | 631 | $3 | $2,133 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -30.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Revenue changed +0.0% from the comparable as-filed period.
Stock-based compensation changed -31.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-342348